Stocks · News reference
Curaleaf condemns Aurora Cannabis for rejecting its enhanced proposal, accusing the board of obstructing engagement and fair value.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (NASDAQ:ACB), the Canadian-based leading global medical cannabis company, today reconfirms that the Board of Directors (the "Board"), on
Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.
Filed: 2026-10-19 AccNo: 0001756770-26-000130 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits